Natural HLA-B*2705 Protein Ligands with Glutamine as Anchor Motif

IMPLICATIONS FOR HLA-B27 ASSOCIATION WITH SPONDYLOARTHROPATHY*

Received for publication, January 22, 2013, and in revised form, February 12, 2013. Published, JBC Papers in Press, February 19, 2013, DOI 10.1074/jbc.M113.455352

Susana Infantes‡, Elena Lorente§, Eilon Barnea‡, Ilan Beer‡, Alejandro Barriga‡, Fátima Lasala‡, Mercedes Jiménez‡, Arie Admon‡, and Daniel López‡

From the ‡Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda (Madrid), Spain, the §Technion-Israel Institute of Technology, Haifa 32000, Israel, and the ¶IBM Haifa Research Laboratory, Haifa 3498825, Israel

Background: HLA-B*2705 is strongly associated with ankylosing spondylitis (AS).

Results: A change in the position (P) 2 anchor motif was detected in the 3% of HLA-B*2705 ligands identified, which showed significant homology to pathogenic bacterial sequences.

Conclusion: Unusual HLA-B*2705 ligands bind with different conformations to both AS-associated and non-AS-associated HLA-B*2705 subtypes.

Significance: This could be sufficient to initiate autoimmune damage in patients with AS-associated subtypes.

The presentation of short viral peptide antigens by human leukocyte antigen (HLA) class I molecules on cell surfaces is a key step in the activation of cytotoxic T lymphocytes, which mediate the killing of pathogen-infected cells or initiate autoimmune tissue damage. HLA-B*2705 is a well known class I molecule that is used to study both facets of the cellular immune response. Using mass spectrometry analysis of complex HLA-bound peptide pools isolated from large amounts of HLA-B*2705 cells, we identified 200 naturally processed HLA-B*2705 ligands. Our analyses revealed that a change in the position (P) 2 anchor motif was detected in the 3% of HLA-B*2705 ligands identified. B*2705 class I molecules were able to bind these six GlnP2 peptides, which showed significant homology to pathogenic bacterial sequences, with a broad range of affinities. One of these ligands was able to bind with distinct conformations to HLA-B*2705 subtypes differentially associated with ankylosing spondylitis. These conformational differences could be sufficient to initiate autoimmune damage in patients with ankylosing spondylitis-associated subtypes. Therefore, these kinds of peptides (short, with GlnP2, and similar low affinity to all HLA-B*2705 subtypes tested but with unlike conformations in differentially ankylosing spondylitis-associated subtypes) must not be excluded from future researches involving potential arthritogenic peptides.

Proteolytic degradation of self-proteins and pathogenic proteins in the cytosol by the combined actions of the proteasomes and degradative peptidases generates peptides, mostly of 8–10 residues, that are translocated to the endoplasmic reticulum lumen by the transporter associated with antigen processing (TAP)2 molecules. These short peptides assemble with human leukocyte antigen (HLA) class I heavy chain and β2-microglobulin molecules (1). Typically, this interaction is made possible by two major anchor residues at position 2 (P2) and the C terminus (CΩ) of the antigenic peptide (2, 3) that are deeply inserted into specific pockets of the antigen recognition site of the HLA class I molecule (4, 5). Finally, the stable trimolecular peptide-HLA-β2-microglobulin complexes are transported to the cell membrane and presented for cytotoxic T lymphocyte recognition (6). This recognition of pathogenic or self-peptide ligands can lead to the beneficial killing of pathogen-infected cells or initiate a pathologic autoimmune damage respectively.

One of the most interesting class I HLA alleles is the HLA-B*27, which is strongly associated with ankylosing spondylitis (AS), a chronic inflammatory spondyloarthritis (7). Furthermore, although most of the HLA-B*27 subtypes are strongly associated with AS, HLA-B*2706 and -B*2709 are either not associated or perhaps only weakly associated with this disease (reviewed in Ref. 8), suggesting that this polymorphism subtype modulates disease susceptibility. Previous studies show an unambiguous functional distinction between the closely related AS-associated B*2704 and non-AS-associated B*2706 subtypes (9). However, after four decades of research, the basis for this association remains an enigma. Several hypotheses, each based on a particular feature of the HLA-B*27 gene, have been proposed to elucidate this intriguing association, but none have yet satisfactorily explained the mechanism and the differential association of HLA-B*27 subtypes with disease. The arthritogenic peptide hypothesis (10) assumes that HLA-B*27 can present a microbial epitope, eliciting a normal cytotoxic T lymphocyte response against the pathogen. Unfortunately, some of these cytotoxic T lymphocytes would cross-react with an autol-

2 The abbreviations used are: TAP, transporter associated with antigen processing; AS, ankylosing spondylitis; B27-C1R, HMy2.C1R transfected with HLA-B*2705; P2, position 2; μLC-MS/MS, micro-tandem liquid chromatography/mass spectrometry.

This is an Open Access article under the CC BY license.
Natural HLA-B27 Peptidome with GlnP2

ogous self-ligand also presented by this molecule and show molecular mimicry with the primary pathogenic epitope. This cross-reaction promotes the autoimmune tissue injury and inflammation. In this hypothesis, the differential binding or immune recognition of either microbial or mimetic self-peptide(s) between the HLA subtypes explains the disparity in association with AS. The interest in this hypothesis has been highly renewed by recent studies on the role of the interaction between HLA-B27 and the endoplasmic reticulum aminopeptidase involved in the trimming of peptides for HLA class I antigen presentation, ERAP1 (11, 12).

The major outstanding feature of HLA-B*2705 specificity is its almost mandatory requirement for Arg at P2 (SYFPEITHI database (3)). In contrast, two ligands with GlnP2 were identified (13, 14). To broaden this study, by means of an immunoproteomics analysis of peptide pools isolated from HLA-B27+ cells the current study identifies, in addition to several hundred HLA-B27 ArgP2 self-ligands, a small fraction of peptides contained Gln at the P2 anchor motif. These peptides bind to HLA-B27 subtypes with differential association with AS and show significant homology to arthritogenic bacterial sequences.

**EXPERIMENTAL PROCEDURES**

**Cell Lines and Antibodies**—B27-C1R is an HLA-B*2705 transfectant (15) of the human lymphoid cell line HMy2.C1R (C1R) that expresses endogenous HLA class I antigens at low levels (16). RMA-S is a TAP-deficient murine cell line that expresses the mouse H-2b haplotype (17). The RMA-S transfectant cells expressing HLA-B*2705 (18), -B*2704 (19), or -B*2706 (19) have been previously described. All cell lines were cultured in RPMI 1640 supplemented with 10% fetal bovine serum and 5 μM β-mercaptoethanol. The monoclonal antibodies (mAbs) used in this study were W6/32 (specific for a monomorphic HLA-A, -B, and -C determinant) (20) and ME1 (which is specific for HLA-B27, -B7, and -Bw22) (21).

**Synthesis of Peptides**—Peptides were synthesized in a peptide synthesizer (model 433A; Applied Biosystems, Foster City, CA) and purified by reverse-phase HPLC. The molecular mass of peptides was established with MALDI-TOF MS, and composition was determined by μLC-MS/MS.

**Isolation of HLA-bound Peptides**—HLA-bound peptides were isolated from 4 × 10^10 B27-C1R transfectant cells as described previously (22). Cells were lysed in 1% IGEPAI CA-630 (Sigma), 20 mM Tris/HCl buffer, and 150 mM NaCl, pH 7.5, in the presence of a protease inhibitor mixture. HLA-peptide complexes were isolated by affinity chromatography of the soluble fraction with the W6/32 mAb. HLA-bound peptides were eluted at room temperature with 0.1% aqueous trifluoroacetic acid (TFA) and concentrated with a Centricon 3 column (Amicon, Beverly, MA), as described previously (22).

**Electrospray-Ion Trap Mass Spectrometry Analysis**—Peptide mixtures recovered after the ultrafiltration step were concentrated with Micro-Tip reverse-phase columns (C18, 200 μl, Harvard Apparatus, Holliston, MA). Each C18 tip was equilibrated with 80% acetonitrile in 0.1% TFA, washed with 0.1% TFA, and then loaded with the peptide mixture. The tip was then washed with an additional volume of 0.1% TFA, and the peptides were eluted with 80% acetonitrile in 0.1% TFA. Peptide samples were then concentrated to ~18 μl using vacuum centrifugation.

Recovered HLA class I peptides were analyzed in three HPLC procedures by μLC-MS/MS using an Orbitrap XL mass spectrometer (Thermo Electron) fitted with a capillary HPLC column (Eksigent, Dublin, CA). The peptides were resolved on a homemade ReproSil C18 capillary column (75-μm inner diameter) with a 7–40% acetonitrile gradient for 2 h in the presence of 0.1% formic acid, as in Ref. 22. The seven most intense masses that exhibited single-, double-, and triple-charge states were selected for fragmentation by collision-induced dissociation from each full mass spectrum.

**Database Searches**—Pep-Miner (23) was used for peak list generation of the μLC-MS/MS data. The HLA peptides were identified using the following search engines: Pep-Miner (23); Proteome Discoverer 1.0 SP1 (Thermo Electron), combining the results of Sequest 3.31 and Bioworks Browser 3.3.1 SP1 (Thermo Electron) (24); and Mascot (server 2.2, Matrix Science) (25), using the human and the viral sections of the National Center for Biotechnology Information (NCBI) database, which includes 448,769 proteins. The search was not limited by enzymatic specificity, the peptide tolerance was set to 0.005 Da, and the fragment ion tolerance was set to 0.5 Da. Identified peptides were selected if the following criteria were met: Pep-Miner score above 80; Mascot score above 20; Sequest Xcorr >1.7 for singly charged, >2.2 for doubly charged, and >2.9 for triply charged peptides; P_pep less than 1 × 10^-4 with Bioworks Browser; Proteome Discovered score higher than 20; and mass accuracy of 0.005 Da (22). When the MS/MS spectra fitted more than one peptide, only the highest scoring peptide was analyzed. The false positive rate for peptide identification was set to 2% based on the search of a reversed database. In addition, the corresponding synthetic peptides were made, and their manually identified MS/MS spectra were used to confirm the assigned sequence of HLA-B27 ligands.

**MHC/Peptide Stability Assays**—The following synthetic peptides were used as controls in complex stability assays: Flu NP (SRYWAIRTRL, HLA-B27-restricted) (26) and C4CON (QYDADVYKL, HLA-Cw4-restricted) (27). RMA-S B*2705 transfectant cells, a cell line deficient in TAP that expresses low levels of cell surface MHC class I, were incubated at 26 °C for 16 h in RPMI 1640 medium supplemented with 10% heat-inactivated FBS. This allows the expression of empty MHC class I molecules (without antigenic peptide) at the cellular membrane that are stable at 26 °C but not at 37 °C. The cells were washed and incubated for 2 h at 26 °C with various concentrations of peptide in the same medium. The cells were maintained at 37 °C for an additional 4 h and then collected for flow cytometry. This method allows empty MHC class I molecules to become internalized and can thus discriminate between bound and unbound peptides. MHC expression was measured using 100 μl of hybridoma culture supernatant containing ME1 (anti-HLA-B27) mAb as described previously (28). Data were acquired on a FACSCalibur flow cytometer (BD Biosciences) and analyzed using CellQuest Pro 2.0 software (BD Biosciences). Cells incubated without peptides exhibited peak fluorescence intensities close to the background staining observed with secondary antibody alone. The fluorescence index was cal-

APRIL 12, 2013 • VOLUME 288 • NUMBER 15 JOURNAL OF BIOLOGICAL CHEMISTRY 10883
Natural HLA-B27 Peptidome with GlnP2

TABLE 1
Summary of endogenous ligands with Gln2 detected by MS/MS analysis
CTCL, cutaneous T-cell lymphoma.

<table>
<thead>
<tr>
<th>Sequence</th>
<th>Protein</th>
<th>Position</th>
<th>gi</th>
</tr>
</thead>
<tbody>
<tr>
<td>GQYGNPLNK</td>
<td>ADAM10</td>
<td>18–26</td>
<td>116496847</td>
</tr>
<tr>
<td>IQRTPKIQ</td>
<td>β2-Microglobulin</td>
<td>21–28</td>
<td>114319011</td>
</tr>
<tr>
<td>IQRTPKQVY</td>
<td>β2-Microglobulin</td>
<td>21–30</td>
<td>114319011</td>
</tr>
<tr>
<td>IQLQEOQLQR</td>
<td>CTCL antigen HD-CL-01/L14-2</td>
<td>545–553</td>
<td>36031016</td>
</tr>
<tr>
<td>RQPQVSI</td>
<td>Hypothetical protein</td>
<td>185–191</td>
<td>113430821</td>
</tr>
<tr>
<td>RQPQNLVR</td>
<td>SF3B2</td>
<td>59–67</td>
<td>119594903</td>
</tr>
</tbody>
</table>

* The new HLA-B27 anchor motif is underlined.

* Previously reported (13, 14).

Calculated for each time point as the ratio of peak channel fluorescence of the sample to that of the control incubated without peptide. Binding of peptides was also expressed as EC50, which is the molar concentration of the peptide at 50% of the maximum fluorescence obtained in a concentration range of 100–0.001 μM.

Statistical Analysis—To analyze statistical significance, an unpaired Student’s t test was used. p values < 0.001 were considered to be significant.

RESULTS

HLA-B*2705 Peptidome—HLA-bound peptide pools were isolated from large amounts of B27-C1R cells. This peptide mixture was subsequently separated by reverse-phase HPLC and analyzed by mass spectrometry. Using several software technologies (see “Experimental Procedures”), 198 fragmentation spectra were resolved with high confidence parameters as peptidic sequences of different human cellular proteins (data not shown). As a control, a reverse database search of the same HLA-B27-bound peptide pool showed a 2% false positive rate.

Arg or Gln as the HLA-B27 P2 Anchor Motif—The classical anchor motif for HLA-B*2705 binding, Arg at the P2 residue (SYFPEITHI database (3)), was present in 193 (97%) of the detected ligands, and no differences with the HLA-B27 ligands previously described were found (data not shown). In contrast, this motif was absent in the other six ligands (Table 1). Although virtually all significant fragments of all MS/MS spectra were assigned as daughter ions of the tentative peptidic sequence (supplemental Figs. 1–6, upper panels), the bioinformatics assignment of each sequence was confirmed by identity with the MS/MS spectrum of each corresponding synthetic peptide (supplemental Figs. 1–6, lower panels). These confirmations of synthetic peptides indicate the correct database assignment of the HLA-B27 peptidome.

Two of the ligands with GlnP2 had been previously detected in an earlier study of the HLA-B*2705 peptidome (14) (Table 1). One peptide was derived from the cartilage-related protein ADAM10, two nested peptides were derived from the mono- morphic β2-microglobulin of the HLA class I molecule, and the last three were derived from a tumor antigen, a hypothetical protein, and the SF3B2 protein, respectively (Table 1).

In summary, these results indicate that a total of six ligands with absent ArgP2 anchor motifs were endogenously processed and presented in the HLA-B*2705 cell line. In addition, these data confirm that GlnP2 is an anchor motif derived from peptides bound to the HLA-B*2705 class I molecule.

GlnP2 Ligands Bind to the B*2705 Molecule—Following a similar strategy to the one used in this study, recent studies have identified several hundred HLA-B27 ligands by immunoprecipitation with the W6/32 mAb of HLA-B27-peptide complexes using the B27-C1R cell line (summarized in the SYFPEITHI database (3)). As these six ligands with GlnP2 do not possess the major HLA-B27 anchor motif ArgP2, one possibility is that they could have a defective interaction with the HLA-B27 class I molecule. To test this hypothesis, MHC/peptide complex stability assays were carried out using TAP-deficient RMA-S cells transfected with HLA-B*2705 and three of the six noncanonical ligands. These included the larger (IQRTPKQVY) and shorter (RQPQVSI) ligands as well as a nonamer (GQYGNPLNK). The GQYGNPLNK synthetic peptide induced similar numbers of HLA- peptide surface complexes to a well-known HLA-B*2705 epitope from the influenza virus, whereas the other two peptides induced fewer HLA-B*2705-peptide complexes (Fig. 1A). In addition, the relative MHC class I affinity was determined for all peptides. The GQYGNPLNK peptide bound to HLA-B*2705 class I molecules with EC50 values in the range commonly observed among natural ligands (Fig. 1B). In contrast, the HLA affinity was substantially less for the IQRTPKQVY (EC50 57 ± 14) and RQPQVSI (EC50 200 ± 21) peptides, and thus, these peptides must be considered as medium and low affinity ligands, respectively (Fig. 1B). These data indicate that all ligands detected in the B27-C1R cell line were endogenously presented in association with the B*2705 molecule and that this molecule could bind peptides with a broad range of affinities.

Binding of the RQPQVSI Peptide to HLA-B*2705 Molecules—Peptides without an N-terminal interaction with the HLA molecule have been identified as endogenously bound to HLA-B39 (29) and the murine MHC class I molecule H-2Dd (30), indicating that canonical MHC-peptide interactions in the P1 pocket are not always necessary for endogenous peptide presentation. Usually, the HLA-B*2705 molecule binds peptides of 8–13 residues (3, 31), but in this study, a 7-mer was found bound to this HLA class I molecule. One possibility for this is that the short RQPQVSI peptide binds to HLA-B27 molecules in the same manner that other peptides lacking the N-terminal binding residue do. Thus, new HLA-B*2705/peptide complex stability assays were carried out exchanging either the ArgP1 or the GlnP2 residues of the RQPQVSI peptide for alanine. Fig. 2 shows similar binding affinities for both the HLA-B*2705 natural ligands and the single Ala-substituted peptides. The exchange of both ArgP1 and GlnP2 residues by Ala abrogated binding to HLA-B*2705 molecules. Collectively, these data indicate that ArgP1 as well as GlnP2 residues of the RQPQVSI
peptide are sufficient to support interactions with class I molecules.

GlnP2 Ligands Bind to HLA-B27 Subtypes with Differential Association with Ankylosing Spondylitis—In contrast to HLA-B*2705, some HLA-B27 subtypes are not associated with AS (reviewed in Ref. 8). Thus, we selected a pair of HLA-B27 subtypes with differential association with this autoimmune disease. Although HLA-B*2706 is not associated with AS, its most related HLA-B27 subtype, B*2704, is an AS-associated subtype. Thus, a comparison of the specific binding of these HLA class I molecules to peptides with noncanonical GlnP2 residues was carried out. The binding to HLA-B*2706 was significantly less than that of B*2704 (and the B*2705) with both the GQYGNPLNK and the IQRTPKIQVY peptides; thus, these peptides must be considered low affinity ligands in the subtype associated with AS (Fig. 3). No differences in binding were found with the RQPQVSI peptide in both subtypes (Fig. 3). In summary, the three GlnP2 peptides studied bound to HLA-B*2706 with relatively low affinity. In addition, the differential binding between the B*2704 and B*2706 subtypes detected with the GQYGNPLNK and IQRTPKIQVY peptides, but not with RQPQVSI peptide, correlated with the previously reported repertoire of ArgP2 peptide specificity of these subtypes, where B*2704 but not B*2706 favors the binding of Tyr or Arg at residue carboxy-terminal of a peptide (P/H9024).
Natural HLA-B27 Peptidome with GlnP2

Homology of GlnP2 Ligands with Pathogenic Bacterial Sequences—A comparison of the sequences of six natural HLA-B27 GlnP2 ligands identified in the current study with 12 species of bacteria associated with HLA-B27-dependent reactive arthritis (33) was carried out. Table 3 shows diverse bacterial sequences that differ from endogenous HLA-B27 peptides by 2–3 residues. Most of these changes are in surface-exposed regions of proteins; thus, they could modulate differential interactions with the T-cell receptor as compared with endogenous cellular HLA-B27 peptides as shown in the HLA-B*2705 crystal structure (34) (PDB: 1HSA). In addition, four proteins with HLA-B27 GlnP2 ligands, ADAM10, β2-microglobulin, cutaneous T-cell lymphoma antigen, and SF3B2, were included in a network of connective tissue disorders and inflammatory disease following analysis with the Ingenuity Pathway Analysis software.

DISCUSSION

In this study, we have investigated several issues concerning the processing of natural HLA-B*2705 ligands, including the analysis of a refined binding motif and the binding of GlnP2 ligands to HLA-B27 subtypes differentially associated with AS. Previously, some HLA-B*2705 ligands with GlnP2 had been described (13, 14). In the present study, this change in the P2 anchor motif was detected in the 3% of HLA-B*2705 ligands identified. Thus, these data confirm the refined HLA-B*2705 binding motif. In addition, five of six ligands identified by mass spectrometry analysis show the preferential residue usage both P1 and/or P2 positions previously described from canonical HLA-B*2705 ligands (14, 35). Thus, the GlnP2 ligands could interact with the pockets of the HLA class I-presenting molecule in the same way those ArgP2 canonical ligands.

Five of the six ligands with GlnP2 were derived from four proteins included in a network of connective tissue disorders. ADAM10 is a chondrocyte-derived metalloproteinase involved in joint pathology (36, 37). The β2-microglobulin is associated with HLA class I heavy chains and reduces HLA-B27 misfolding promoting arthritis and spondylitis in HLA-B27-transgenic rats (38). HD-CL-01 is an antigen of cutaneous T-cell lymphoma, and polyarthritis in the presence of this lymphoma is a phenomenon previously described (39–41). Lastly, SF3B2 is a component of the spliceosome complex (42) that has been linked to rheumatoid arthritis and several connective tissue diseases (43, 44).

All these human HLA-B27 GlnP2 ligands have homology with distinct arthritogenic bacterial sequences that differ from these endogenous HLA-B27 peptides by 2–3 residues. Remarkably, several arthritogenic bacterial sequences possess changes in the ArgP1 of the RQPQVSI sequence that could alter the binding conformations between the different subtypes of HLA-B27 associated or not associated with AS.

The observation that HLA-B*2704 and -B*2706 subtypes share a very broad fraction of ~90% of their peptide repertoires (32) suggests that putative arthritogenic peptides could be confined in a first approximation to a relatively small portion of ligands shared by AS-associated subtypes such as B*2705 and B*2706 that are missing from the B*2706 peptide repertoire.
The self-derived ligands with GlnP2, analyzed in the current study, bind to AS-associated class I subtypes (HLA-B*2705 and -B*2706) with a broad range of affinities, whereas they have shown a low affinity in their interaction with the non-AS-associated HLA-B*2706 allele. Thus, the differences of affinity in self-derived ligands could trigger autoimmune tissue injury in patients with AS-associated subtypes. Therefore, these kinds of peptides (short, with GlnP2, and with similar low affinity to all HLA-B27 subtypes tested but with dissimilar conformations in differentially AS-associated subtypes) must not be excluded from future research involving potential arthritogenic peptides.

In summary, these results inform us about the interaction between unusual GlnP2 self-derived ligands and different HLA-B27 subtypes in the pathogenic role of these class I molecules in the triggering of AS autoimmune disease.

Acknowledgment—We thank Dr. J. A. López de Castro (Centro de Biología Molecular Severo Ochoa, Madrid, Spain) for the cell lines.

REFERENCES


TABLE 2

Binding to HLA-B27 subtypes with differential association to ankylosing spondylitis to synthetic peptide RQPQVSI with Ala substitutions in anchor motifs

<table>
<thead>
<tr>
<th>Subtype</th>
<th>Association with AS</th>
<th>RQPQVSIα</th>
<th>AQPQVSIα</th>
<th>RAPQVSIα</th>
<th>AAPQVSIα</th>
</tr>
</thead>
<tbody>
<tr>
<td>B*2705</td>
<td>Yes</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B*2704</td>
<td>Yes</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
</tr>
<tr>
<td>B*2706</td>
<td>No</td>
<td></td>
<td>+</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

α Binding to HLA-B27 subtypes.
β The substitution for Ala is underlined.
γ ND, not done.

TABLE 3

Alignment of natural HLA-B27 peptides with sequences of bacteria associated with B27-dependent reactive arthritis

CTCL, cutaneous T-cell lymphoma.

<table>
<thead>
<tr>
<th>Peptide</th>
<th>Protein</th>
<th>gi</th>
<th>Species*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q Y G N P L N K</td>
<td>ADAM 10</td>
<td>116496847</td>
<td>Homo sapiens</td>
</tr>
<tr>
<td>Q A M k B</td>
<td>261246210</td>
<td>Salmonella</td>
<td></td>
</tr>
<tr>
<td>N Y S histidine kinase</td>
<td>18869428</td>
<td>Yersinia</td>
<td></td>
</tr>
<tr>
<td>D Q L Q E Q L Q</td>
<td>CTCL tumor antigen</td>
<td>36031016</td>
<td>Homo sapiens</td>
</tr>
<tr>
<td>A Q E minor tail protein</td>
<td>16764280</td>
<td>Salmonella</td>
<td></td>
</tr>
<tr>
<td>Q A E deoxyribonuclease YjIV</td>
<td>74314813</td>
<td>Shigella</td>
<td></td>
</tr>
<tr>
<td>D K H DNA ligase LigB</td>
<td>12344045</td>
<td>Yersinia</td>
<td></td>
</tr>
<tr>
<td>T D K protein ULA455</td>
<td>13358018</td>
<td>Ursuphama</td>
<td></td>
</tr>
</tbody>
</table>

* Natural HLA-B27 Peptidome with GlnP2


tive tissue disease, and systemic lupus erythematosus. *Arthritis Rheum.* 38, 777–785